Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from RELIEF THERAPEUTICS Holding ( (CH:MMTX) ).
MindMaze Therapeutics has gained additional visibility in the capital markets after Baader Bank initiated equity research coverage on its shares with a Buy recommendation and a target price of CHF 1.80. This new analyst coverage, which comes on top of existing research from Edison Group valuing the company at CHF 3.56 per share, underscores growing investor interest in its AI-enabled neurotherapeutic platform and could help support liquidity and valuation as it advances its clinically validated, scalable treatments for neurological conditions.
The most recent analyst rating on (CH:MMTX) stock is a Hold with a CHF1.00 price target. To see the full list of analyst forecasts on RELIEF THERAPEUTICS Holding stock, see the CH:MMTX Stock Forecast page.
More about RELIEF THERAPEUTICS Holding
MindMaze Therapeutics Holding SA is a Geneva-based medical technology company focused on precision neurotherapeutics and brain technology. It develops FDA-cleared and CE-marked digital neurotherapy solutions that combine advanced software, proprietary sensors, and AI-driven data analytics to support recovery for stroke, Parkinson’s disease, and other neurological disorders, spanning hospital, outpatient, and home-based care.
Average Trading Volume: 360,859
Technical Sentiment Signal: Sell
Current Market Cap: CHF76.44M
Find detailed analytics on MMTX stock on TipRanks’ Stock Analysis page.